Wonbiogen원바이오젠

Wonbiogen posted strong trailing profits in H1 2026 but trades near its lows after a weak past month.

Wonbiogen makes wound dressings and supplies pharma companies on an ODM basis, selling its own brand through hospitals, pharmacies and distributors. Trailing twelve-month revenue is ₩37.8B with operating income of ₩9.4B and net income of ₩8.4B, and the stock closed at ₩5,640 on 2026-10-26, a market cap of about ₩40.0B. Free cash flow was negative over the period, and the data does not give forward forecasts.

What stands out

• Trailing operating margin is 24.9% and net margin 22.3%, both above the 2025 full-year levels of 22.5% and about 18%.
• Revenue grew 15.8% in 2025 after 2.8% in 2024, but the data gives no segment or product-level breakdown.
• Trailing free cash flow is negative at about -₩1.5B, while cash of ₩4.1B exceeds borrowings of ₩4.0B.
• The stock is down 5.5% over one month and up 2.5% over three months and 9.1% over one year, trading between ₩4,765 and ₩8,400 over 52 weeks.
• Filings show a half-year report with an amendment in October 2026 and recent facility investment disclosures; news covers a ₩13B facility completion and a new cleanser co-development.

What to watch

• The amended half-year report from October 2026 and any further corrections to filings.
• Whether the trailing free cash flow turns positive as the new ₩13B facility ramps up.
• The data does not include upcoming earnings dates or guidance, so the next results timing is unknown.